Steven Peskin, MD, MBA, FACP: [In regard to coverage of companion diagnostics], if there’s a specific explicit companion diagnostic associated with a targeted therapy or immunotherapy, that companion diagnostic would be covered in conjunction with the assumption that it’s going to be used to decide whether or not to use a particular demonstrated effective immunotherapy, or targeted therapy, or precision therapy. Those would be covered.
It gets a bit greyer [in the] area where there is a broad range of biomarkers that have implications in certain cancers. We’re not sure, yet, what the implications are for therapy, so we’re continuing to very vigorously study those kinds of issues by working with some of our key thought creators (thought leaders) that are helping us to make decisions about the use of biomarkers or the coverage of biomarkers as it relates to oncology care.
There are certain therapies that are known to work very well in select patients but to be of no clinical utility or clinical value in other patients. Again, there are going to be grey areas where the particular immunotherapy is demonstrated to be extremely effective in a certain cohort with a certain biomarker (KRAS or others) but might also be, perhaps, less effective [in other cohorts]. Then, we clearly have situations where it’s ineffective, and maybe even counterproductive. In that sense, we would look for the test to be done prior to the initiation of certain therapies.
[When it comes to] early identification of nonresponders, that is, again, very much aspirational. We’re working with certain clinical partners on more rapid elucidation of nonresponders, using data analytics to more quickly and effectively identify nonresponders, so that we can move on, and, with our clinical organizations, get that patient (perhaps) into a clinical trial or into using another therapy that might be effective in that situation. Or if the situation is such that there are no good alternatives, then we are looking at palliative care as opposed to treatment for that type of care. So, looking for nonresponders is something we are very much working collaboratively with our oncology clinical partners on.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More